关键信息
-
基因名
HLA-A*03:01&B2M&KRAS G12V(VVGAVGVGK) Tetramer
- 应用
-
别名
MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
NP_002107.3 (G25-T305)&P61769
-
表达区间
NP_002107.3 (G25-T305)&P61769 (I21-M119)&VVGAVGVGK
-
分子量
260-265 kDa under Non reducing (N)
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
The study of the HLA-A*03:01/B2M/KRAS G12V (VVGAVGVGK) tetramer recombinant protein focuses on the interaction between major histocompatibility complex (MHC) molecules and tumor-associated peptides in the context of immunotherapy for cancer treatment. The KRAS G12V mutation is critical as it is one of the most common oncogenic mutations found in various cancers, including pancreatic and colorectal cancers. The presentation of the KRAS G12V peptide by HLA-A*03:01, a widely expressed MHC class I molecule, facilitates the recognition of cancer cells by CD8+ cytotoxic T lymphocytes, enhancing the potential for targeted immune responses. By creating a tetramer that combines HLA-A*03:01 with the relevant KRAS G12V peptide, researchers aim to identify and analyze KRAS-specific T cell populations in patients. This approach could lead to better understanding of the immune response against KRAS-mutant tumors and assist in the development of personalized cancer vaccines or immunotherapies that can empower the immune system to effectively combat malignancies. Additionally, insights gained from this research may provide a foundation for exploring other neoantigens in cancer and improving overall treatment strategies.
